As per the clinical data that appeared in the journal titled "Palliative & Supportive Care", hospitalized patients who consumed metered dosing of herbal cannabis via inhaler reported no severe side effects and significant symptom relief.
A study titled "Cannabis treatment in hospitalized patients using the SYQE inhaler: Results of a pilot open-label study", was conducted by a group of Israeli investigators who tried to assess the efficacy, safety, and feasibility of cannabis (administer through metered doses of inhaler) in a group of hospitalized patients. The metered-dose inhaler is good as it allows patients to self-administer precise quantities of non-combustible cannabis (in vaporized form).
The Israeli investigators noted that almost all of the patients who participated in the study reported a reduction in pain symptoms after cannabis therapy. In addition to this, many subjects also reported relief from spasticity and nausea. None of the subjects who participated in the study reported any adverse side effects. Moreover, more than 3/4 of the subjects who participated in the study reported that it was "easy" to use the inhaler.
At the end of the study, the authors were able to conclude the following:
"The current study results have demonstrated the feasibility of administrating cannabis using the SYQE Inhaler, allowing for the first time, to administer small, safe, accurate, precise, and reliable dosages of cannabinoids" in hospital setting."